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Abstract The mic2 mutation dominantly blocks formation of
mannosyl-diinositolphosphorylceramide, the most abundant
sphingolipid of the yeast, Saccharomyces cerevisiae. Interest-
ingly, lack of mannosyl-diinositolphosphorylceramide is not
lethal but is compensated for by increased amounts of
inositolphosphorylceramide and mannosyl-inositolphosphorylcer-
amide in the plasma membrane and Golgi of the mutant. The
level of negatively charged phospholipids in the plasma
membrane of the mic2 strain is markedly reduced; the sterol
composition is not altered. In spite of dramatic changes of its
lipid composition the mutant grows like wild type on complex and
minimal media, under osmotic stress conditions, at low pH, and
in the presence of high ionic strength. While sensitivity to several
drugs is not altered, the mic2 mutant strain becomes resistant to
the polyene antibiotic nystatin.
z 1997 Federation of European Biochemical Societies.
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1. Introduction
As in higher eukaryotic cells, phospholipids, sterols, and
sphingolipids are the major membrane lipid components of
the yeast, Saccharomyces cerevisiae. The sphingolipids of
this microorganism contain a long-chain amino alcohol, phy-
tosphingosine, amide-linked to a very long-chain fatty acid
(mostly a C
26
hydroxy fatty acid), and inositol phosphate or
mannosylated inositolphosphate as polar head group. The
three classes of yeast sphingolipids, IPC
1
, MIPC, and
M(IP)
2
C [1], are intermediates and products of a common
biosynthetic pathway. IPC is produced in the endoplasmic
reticulum by IPC synthase that catalyzes the condensation
of inositolphosphate with ceramide [2,3]. After transport to
the Golgi, IPC is converted to MIPC with GDP-mannose as
the carbohydrate donor [4]. Finally, introduction of the sec-
ond inositolphosphate group results in the formation of
M(IP)
2
C in the Golgi [5].
Only few yeast mutants defective in the biosynthesis of
sphingolipids are known. The phytosphingosine auxotrophic
mutants, lcb1 and lcb2 (long-chain base auxotrophic) are de-
fective in serine palmitoyltransferase [6]. Both genes are essen-
tial, and mutants are not viable unless supplemented with
phytosphingosine. An lcb1 mutant carrying the SLC1
(sphingolipid compensation) suppressor gene is viable in the
absence of long-chain bases. These suppressor mutants, how-
ever, synthesize novel phosphatidylinositol derivatives with a
C
26
fatty acid in the sn-2 position and structurally mimic
sphingolipids [7]. The slc1 mutant cannot grow at low pH,
high salt concentration, or high temperature [8] indicating
that the novel phosphatidylinositol species cannot fully com-
pensate for the lack of sphingolipids. Based on the ¢nding
that the SLC1 gene complements the growth phenotype of
an E. coli acyltransferase mutant plsC, Slc1p was suggested
to be a fatty acyltransferase [9]. A Ca
2
hypersensitive muta-
tion, csg2, was found to a¡ect the synthesis of mannosylated
sphingolipids [10]. Csg2p is required for Ca
2
regulation, and
supplementation with phytosphingosine reverses the Ca
2
sen-
sitive phenotype of the csg2 strain. Suppressor mutants of
csg2, scs, also have an altered sphingolipid metabolism [11].
Scs1p is identical to Lcb2p, the regulatory subunit of serine
palmitoyltransferase. These observations led to the idea that
ceramide synthesis in yeast is either regulated by Ca
2
and/or
is required for Ca
2
homeostasis.
Here we report isolation of a novel yeast mutant, termed
mic2, which is defective in the last step of the sphingolipid
biosynthetic pathway, the formation of M(IP)
2
C. The mutant
phenotype is described, and possible roles of M(IP)
2
C in plas-
ma membrane function are discussed.
2. Material and methods
2.1. Yeast strains and culture conditions
Wild type strains of Saccharomyces cerevisiae, W303 (MATa, ura3,
trp1, leu2, ade2, his3, can1) and X2180-1A (MATK, SUC2, mal, gal2,
CUP1), the temperature-sensitive secretory mutant sec1 (provided by
R. Schekman), and the M(IP)
2
C de¢cient strain mic2 (MATK, ura3,
trp1, leu2, ade2, his3) were used throughout this study. Cells were
grown either in complex medium (YPD) containing 3% glucose, 2%
peptone, and 1% yeast extract (Difco), or in inositol-free medium [12]
under aerobic conditions at 30³C or 24³C. Growth of yeast cells was
determined by measuring the optical density at a wavelength of 600
nm.
The mic2 mutation was initially detected in the genetic background
of a temperature-sensitive sec1 mutant. To isolate the mic2 strain, sec1
was backcrossed to W303, diploids were sporulated, and tetrads were
dissected by standard procedures [13]. Tetrads were analyzed for tem-
perature sensitivity and M(IP)
2
C formation (see below), and M(IP)
2
C
de¢cient strains that were not temperature sensitive were isolated. The
mic2 mutant was established after four rounds of backcrossing of the
mutant to the wild type strain W303.
Drug resistance of strains was tested in plate assays. Sterilized YPD
agar was cooled to 50³C, and drugs were added from stock solutions
and mixed with the agar. Plates were poured and used the following
day to avoid loss of activity of the drugs. Yeast strains to be tested
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were suspended in liquid YPD, and 5 Wl spots were applied to plates.
Plates were incubated for 1^3 days at 30³C.
2.2. Isolation and characterization of yeast subcellular membranes
Plasma membrane was isolated by the method of Serrano [14], and
the Golgi-fraction was prepared as described by Leber et al. [15]. The
quality of the preparations and cross-contamination with other organ-
elle membranes were judged by immunoblot analysis and measure-
ment of marker enzyme activities as described by Zinser and Daum
[16].
Proteins were quanti¢ed by the method of Lowry et al. [17], SDS-
PAGE was carried out as described by Laemmli [18], and Western
blot analysis was performed by the method of Haid and Suissa [19].
Immunoreactive proteins were detected by ELISA with peroxidase-
and phosphatase-conjugated goat anti-rabbit secondary antibodies.
2.3. Analysis of lipids
Labeling of yeast sphingolipids with [
3
H]inositol, extraction of
sphingolipids from subcellular fractions, thin-layer chromatographic
separation and quanti¢cation were performed as described previously
[20]. Phospholipids and sterols were extracted by the procedure of
Folch et al. [21]. Individual phospholipids were separated by two-
dimensional thin-layer chromatography on Silica gel 60 plates using
chloroform/methanol/25% NH
3
(65:35:5, per vol.) as ¢rst, and
chloroform/acetone/methanol/acetic acid/H
2
O (50:20:10:10:5, per
vol.) as second developing solvent. Phospholipids were visualized by
iodine staining, scraped o¡ the plate, and quanti¢ed by the method of
Broekhuyse [22]. For ergosterol quanti¢cation samples and standards
were applied to thin-layer plates, chromatographed using light petro-
leum/diethylether/acetic acid (70:30:2, per vol.), and scanned at 275
nm using a Shimadzu dual-wavelength chromato scanner CS-930. In-
dividual sterols were analyzed after alkaline hydrolysis [23] of the lipid
extract by gas chromatography-mass spectrometry using a Hewlett-
Packard 5892 II plus and a Hewlett-Packard MSD 5972 mass selective
detector. The column used was HP-5MS, injector temperature was
280³C, and detector temperature 300³C.
2.4. Anisotropy measurement
Fluidity of the plasma membrane was determined in vitro by meas-
uring the £uorescence anisotropy of trimethylammonium diphenyl-
hexatriene (TMA-DPH) probe. Samples containing 100 Wg membrane
protein were incubated with 2.7 nmol TMA-DPH for 30 min at 30³C.
Fluorescence measurements were carried out using a Shimadzu RF
540 spectro£uorimeter as described previously [24].
3. Results and discussion
Labeling experiments with [
3
H]inositol of a number of tem-
perature-sensitive yeast secretory mutants revealed that one of
these strains, namely a sec1 mutant, had a second mutation in
its genetic background that manifested itself by the absence of
the major yeast sphingolipid, M(IP)
2
C [25]. This mutant was
backcrossed to the wild type strain W303, and tetrads were
screened for temperature sensitivity and M(IP)
2
C synthesis.
This analysis revealed that the defect in the biosynthesis of
M(IP)
2
C and the sec1 mutation were not linked. Four addi-
tional rounds of backcrossing resulted in the isolation of the
temperature-insensitive mic2 mutant. Fig. 1 shows the pattern
of [
3
H]inositol-labeled lipids of the original sec1 strain and
two spore-derived colonies of a tetrad from backcrosses
with the wild type W303. One of these strains (Fig. 1, lanes
B) lacked M(IP)
2
C, whereas M(IP)
2
C was detectable in the
other (Fig. 1, lanes A). The original sec1 strain does not form
M(IP)
2
C. IPC and MIPC are present at comparable levels in
all strains. The M(IP)
2
C

/M(IP)
2
C
3
phenotype segregated
2:2 indicating a single chromosomal mutation. A heterozy-
gous diploid strain mic2/MIC2 did not produce M(IP)
2
C in-
dicating that the mic2 mutation is dominant.
What are the cell biological consequences caused by the
mic2 mutation? To answer this question two subcellular frac-
tions were analyzed in detail : the plasma membrane, which is
the compartment with the highest concentration of M(IP)
2
C
in wild type cells [26,20], and the Golgi, the site of MIPC and
M(IP)
2
C synthesis [5]. Comparing the sphingolipid composi-
tion of the plasma membrane and the Golgi of mic2 and wild
type (Table 1) demonstrated that in both compartments of the
mic2 mutant M(IP)
2
C was not detectable. The ratio of total
sphingolipids to protein is markedly higher in the plasma
membrane of mic2 than in wild type (Table 2). Thus, lack
of M(IP)
2
C in the mutant is apparently compensated for by
increased amounts of IPC and MIPC.
The ergosterol concentration in the plasma membrane of
the mutant was comparable to the wild type, whereas the
phospholipid content in the plasma membrane of mic2 was
approximately 30% lower than in the control (Table 2). Com-
parison of the phospholipid composition of the plasma mem-
brane of mic2 and wild type revealed that the lack of M(IP)
2
C
markedly a¡ects the ratio of negatively charged to uncharged
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Table 1
Sphingolipid composition of plasma membrane and Golgi of mic2 and wild type
Strain Membrane IPC/protein MIPC/protein M(IP)
2
C/protein
(nmol/mg) (nmol/mg) (nmol/mg)
X2180 Plasma membrane 51 106 81
mic2 Plasma membrane 134 349 ND
X2180 Golgi 155 18 47
mic2 Golgi 3 108 ND
ND, not detectable; 3, not determined. Plasma membrane and Golgi from mic2 and the parental wild type X2180 were isolated and analyzed for
their amount of sphingolipids as outlined in Section 2. Data shown are mean values of three independent experiments with a mean deviation of
þ 10%.
Fig. 1. The yeast mutant mic2 is de¢cient in conversion of MIPC to
M(IP)
2
C. Lipids of two isogenic spores of a tetrad (A: MIC2 ; B:
mic2) and the original sec1 strain were labeled with [
3
H]inositol at
temperatures indicated, extracted and analyzed by thin-layer chro-
matography as described in Section 2.
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phospholipids (Table 3): the plasma membrane of wild type
cells contains approximately 55%, whereas that of the mic2
mutant contains only 41% negatively charged phospholipids.
This alteration is mainly due to a decrease of phosphatidyl-
serine and phosphatidylinositol, and an increase of phospha-
tidylethanolamine in the plasma membrane of mic2. Thus, the
elevated level of negatively charged total sphingolipids in the
mutant plasma membrane appears to be compensated for by a
decrease of negatively charged phospholipids.
We next investigated whether the altered sphingolipid and
phospholipid composition of the plasma membrane of the
mic2 mutant has an e¡ect on membrane £uidity. Anisotropy
measurements using trimethylamino-diphenyl-1,3,5-hexatriene
(TMA-DPH) as a probe for lipid mobility or £exibility in the
membrane demonstrated that this is not the case. The aniso-
tropy of TMA-DPH in the plasma membrane of both mutant
and wild type strain was 0.27. This result suggests that the
increased levels of IPC and MIPC together with the altered
phospholipid composition of the mic2 mutant compensated
for the absence of M(IP)
2
C in such a way as to keep the
membrane £uidity constant.
The altered lipid composition of the mic2 mutant might be
expected to cause an abnormal growth phenotype. Surpris-
ingly, the mutant grew like wild type under various conditions
tested, such as on rich medium (YPD), minimal medium, on
di¡erent carbon sources (glucose, ethanol, lactate), in the
presence of 1 M NaCl, 1 M sorbitol plus 0.5 M NaCl, at
pH 3, and on inositol-free medium. Di¡erent growth temper-
atures (10³C, 24³C, 30³C, and 37³C) also did not signi¢cantly
a¡ect cell viability. Similarly, the presence of 0.1 M Ca
2
,
Mg
2
, or Li

, and 1 mM Cu
2
in the growth medium did
not speci¢cally a¡ect growth of mic2. In contrast to the csg2
mutant, mic2 is not sensitive to Ca
2
at concentrations of 0.1
M indicating that IPC and/or MIPC but not M(IP)
2
C a¡ect
Ca
2
homeostasis.
Drug sensitivity of mic2 was tested with cycloheximide (0.1^
0.3 Wg/ml; inhibitor of cytosolic protein synthesis), chloram-
phenicol (10^50 Wg/ml; inhibitor of protein synthesis in mito-
chondria), valinomycin (250 Wg/ml; ion carrier destroying
membrane potential), Brefeldin A (50 Wg/ml; disassembling
Golgi in mammalian cells and yeast strains defective in certain
steps of sterol metabolism [27]), and terbina¢ne (10^70 Wg/ml;
inhibitor of fungal squalene epoxidase) [28]. None of these
drugs speci¢cally a¡ected growth of the mutant. In contrast,
nystatin, a polyene antibiotic [29], at a concentration of 10 Wg/
ml inhibited growth of the wild type strain but not that of
mic2. Tetrad analysis con¢rmed that nystatin resistance co-
seggregated with the block in M(IP)
2
C synthesis (data not
shown).
The antimycotic drug nystatin has been described to inter-
act with sterol of the plasma membrane forming pores, caus-
ing leakage of cellular constituents and ultimately cell death
[29]. Some sterol mutants such as erg3 and erg6, which have
an altered sterol composition of the plasma membrane, are
resistant to nystatin [30,31], whereas others, such as erg4,
remain nystatin sensitive (D. Zweytick, unpublished results).
These ¢ndings may be explained by similar interaction of
nystatin with sterols di¡erent from ergosterol, such as ergo-
sta-5,7,22,24(28)-tetraenol accumulating as the end-product in
the erg4 mutant. On the other hand, Kerridge [29] reported
that strains with apparently similar sterol composition exhib-
ited markedly di¡erent sensitivity to polyene antibiotics. The
author suggested that additional factors may be responsible
for sensitivity to these drugs. Sphingolipids may be a target
for nystatin similar to or in combination with ergosterol. In-
teraction of nystatin with M(IP)
2
C in combination with ergo-
sterol is compatible with the idea that membrane domains
enriched in the two lipid classes may exist in the plasma mem-
brane. Such detergent insoluble membrane domains of the
yeast plasma membrane have recently been described [32].
Studies on lipid sorting in epithelial cells [33] suggest that
sphingolipids and cholesterol aggregate in the lumenal lea£et
of Golgi membranes. These aggregates may then be preferen-
tially included into anterograde vesicles which transport
sphingolipids and sterols to the cell periphery. In yeast, trans-
port of sphingolipids from their site of synthesis to the plasma
membrane has been shown to follow the secretory pathway
[5,25]. Enrichment of ergosterol in secretory vesicles [34] sug-
gests participation of the secretory machinery in ergosterol
transport to the plasma membrane. Thus, a sterol/sphingoli-
pid co-transport may also function in yeast and contribute to
the formation of ergosterol/M(IP)
2
C-rich domains in the plas-
ma membrane. If nystatin preferentially interacts with these
domains, lack of one component may lead to resistance
against the drug.
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